Abstract |
T cells genetically engineered to express chimeric antigen receptors (CAR) have shown unprecedented results in pivotal clinical trials for patients with B cell malignancies or multiple myeloma (MM). However, numerous obstacles limit the efficacy and prohibit the widespread use of CAR T cell therapies due to poor trafficking and infiltration into tumor sites as well as lack of persistence in vivo. Moreover, life-threatening toxicities, such as cytokine release syndrome or neurotoxicity, are major concerns. Efficient and sensitive imaging and tracking of CAR T cells enables the evaluation of T cell trafficking, expansion, and in vivo characterization and allows the development of strategies to overcome the current limitations of CAR T cell therapy. This paper describes the methodology for incorporating the sodium iodide symporter (NIS) in CAR T cells and for CAR T cell imaging using [18F]tetrafluoroborate-positron emission tomography ([18F]TFB-PET) in preclinical models. The methods described in this protocol can be applied to other CAR constructs and target genes in addition to the ones used for this study.
|
Authors | Reona Sakemura, Michelle J Cox, Aditya Bansal, Claudia Manriquez Roman, Mehrdad Hefazi, Cynthia J Vernon, Dianna L Glynn, Mukesh K Pandey, Timothy R DeGrado, Elizabeth L Siegler, Saad S Kenderian |
Journal | Journal of visualized experiments : JoVE
(J Vis Exp)
Issue 180
(02 17 2022)
ISSN: 1940-087X [Electronic] United States |
PMID | 35253798
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Video-Audio Media)
|
Chemical References |
- Receptors, Antigen, T-Cell
- Receptors, Chimeric Antigen
|
Topics |
- Humans
- Immunotherapy, Adoptive
(methods)
- Multiple Myeloma
(diagnostic imaging, therapy)
- Positron Emission Tomography Computed Tomography
(methods)
- Receptors, Antigen, T-Cell
(genetics)
- Receptors, Chimeric Antigen
(genetics)
- T-Lymphocytes
|